循环miRNA-208a在射血分数降低性心力衰竭的诊断价值研究

doi:10.3969/j.issn.1006-6233.2023.10.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1674 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical value of circulating miRNA-208a expression levels in the diagnosis of heart failure with reduced ejection fraction (HFrEF). Methods: From January 2021 to December 2022, 120 patients with heart failure (HF) admitted to the Department of Cardiovascular Medicine of our hospital were selected. Among them, 56 patients with HFrEF were included in the HFrEF group, 64 patients with non-HFrEF were included in the non-HFrEF group, and 60 healthy people in the same period were selected as the control group. Left ventricular ejection fraction (LVEF), left ventricular shortening fraction (LVFS), left atrial diameter (LAD), and left ventricular mass index (LVMI) were measured by echocardiography, Detection of miRNA-208a β- Myosin heavy chain( β- MHC) mRNA expression, and the serum level of N-terminal pro-brain natriuretic peptide precursor (NT-proBNP) was measured by electrochemiluminescence method. Results: LVEF and LVFS in HFrEF group and non-HFrEF group were significantly lower than those in the control group, while LAD and LVMI were significantly higher than those in the control group (P<0.05); LVEF and LVFS in HFrEF group were significantly lower than those in non-HFrEF group, and LAD and LVMI were significantly higher than those in non-HFrEF group (P<0.05). Serum NT-proBNP and miRNA-208a in HFrEF group and non-HFrEF group β- The expression of MHC mRNA was significantly higher than that of the control group. The serum NT-proBNP and miRNA-208a β- The expression of MHC mRNA was significantly higher than that of non-HFrEF group (P<0.05). The expression of miRNA-208a in three groups was negatively corre- lated with LVEF and LVFS, and with LAD, LVMI, NT-proBNP and β- MHC mRNA was positive- ly correlated and the difference was statistically significant (P<0.05). The area under curve (AUC) of miRNA-208a in diagnosis of HFrEF is 0.757, the best cut-off value is 5.19, the Jordan index is 0.417, the sensitivity is 89.29, and the specificity is 52.42%. The AUC of the combined diagnosis ofSerum NT-proBNP, miRNA-208a and β- MHC mRNA is 0.996, the best cut-off value is 0.592, the Jordan index is 0.956, the sensitivity is 96.43%, and the specificity is 99.19%. Conclusion: The expression of miRNA-208a in the circulating blood of patients with HFrEF is significantly incre- ased, which can be used as a biomarker for diagnosis of HFrEF, and can be compared with NT-proBNP β- The combined application of MHC mRNA has better diagnostic efficacy.

Key words： MiRNA-208a Ejection fraction Heart failure Diagnostic value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Qian
	LI Dong
	LI Yu
	et al

Cite this article:

GONG Qian,LI Dong,LI Yu, et al. Diagnostic Value of Circulating miRNA-208a in Heart Failure with Reduced Ejection Graction[J]. HeBei Med, 2023, 29(10): 1698-1704.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.10.022 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I10/1698

[1] 陈建桥,刘宏斌.射血分数保留的心力衰竭的心肌纤维化及炎性相关标志物[J].中华老年心脑血管病杂志,2021,23(2):208-210.
[2] 陈东,董玲玲,黄宏,等.静息心率与射血分数降低性心力衰竭伴心房颤动患者预后的关联[J].中华高血压杂志,2021,29(10):986-990.
[3] Cruz M S,Silva A,Souza K,et al.miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure[J].Heart Failure Reviews,2020,25(2):321-329.
[4] 王盛尧,陈宇,谭顺林.慢性心力衰竭患者血清微小RNA-29b和血小板源性生长因子水平与病情严重程度、心室重构的相关性[J].广西医学,2021,43(22):2669-2674.
[5] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志(中英文),2018,2(4):196-225.
[6] 安东,李树仁,罗飞,等.射血分数轻度降低的心力衰竭患者应用钠-葡萄糖共转运蛋白2抑制剂的研究进展[J].中国全科医学,2022,25(21):2680-2685.
[7] 桂燕萍,陈晔芬,施仲伟,等.超声心动图右室面积变化分数筛查左心室射血分数降低的心力衰竭患者心脏同步性研究[J].诊断学理论与实践,2022,21(3):331-335.
[8] 党彩静,赵文淑,徐琳,等.不同性别重症心力衰竭患者的临床特点及预后影响因素的分析[J].中国循环杂志,2021,36(11):1089-1095.
[9] Mitchell P S,Parkin R K,Kroh E M,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc Natl Acad Sci U S A,2008,105(30):10513-10518.
[10] Schulze P C.A Review on the evolving roles of miRNA-based technologies in diagnosing and treating heart failure[J].Cells,2021,10(11):3191.
[11] JinL.The Therapeutic Effect of miRNA-19a/19b on heart failure in mice and the mechanism of myocardial regeneration and repair[J].Cellular and molecular biology,2021,67(5):202-209.
[12] 杨瑞霞,何亚州,王龙龙,等.温阳贴贴敷涌泉穴治疗慢性心力衰竭阳虚证的临床疗效观察[J].湖南中医药大学学报,2022,42(10):1705-1710.
[13] Zhou H,Tang W,Yang J,et al.MicroRNA-related strategies to improve cardiac function in heart failure[J].Frontiers in cardiovascular medicine,2021,19(8):1613.
[14] Kura B,Szeiffova Bacova B,Kalocayova B,et al.Oxidative stress-responsive microRNAs in heart injury[J].Int Mol Sci,2020,21(1):358.